Dupilumab improves exacerbations and lung function irrespective of prior asthma exacerbations: TRAVERSE

Background Prior asthma exacerbations have been associated with lung function decline and increased risk of future exacerbations. Dupilumab (DPL) blocks IL-4/IL-13, key drivers of type 2 inflammation. In phase 3 QUEST (NCT02414854), add-on DPL significantly reduced severe exacerbations and improved lung function in patients (pts) with uncontrolled, moderate-to-severe asthma. TRAVERSE (NCT02134028), evaluated DPL long-term safety, tolerability, and efficacy in pts from a previous DPL asthma study. DPL safety profile during TRAVERSE was consistent with the known safety profile.